Post by Theodore Plesset

The CDMO "capacity race" is officially over. ❌ For years, the biggest question a biotech sponsor asked was simple: "Who has an open suite or available capacity right now?" But in today's market, the conversation has fundamentally shifted. The biggest question keeping innovators up at night is no longer about space—it’s about risk. Sponsors aren't just looking for suppliers to rent GMP suites from; they are actively hunting for integrated development partners who can reduce their regulatory, technical, and molecule-to-market development risk. The next era of outsourcing will not be won by the largest footprints. It will be won by the CDMOs that build differentiated technology platforms and become impossible to replace. 👇 To the CDMO Leaders in my network: How is your team shifting its commercial and technical messaging to match this new paradigm? Are you positioning as a supplier, or are you truly embedding yourselves in your customer's innovation journey? Swipe through the carousel below to see how the formula for CDMO success is changing. #CDMO #Biotech #PharmaceuticalManufacturing #LifeSciences #ClinicalDevelopment #DrugDevelopment #BarringtonJames